Beam Therapeutics (BEAM) Accumulated Depreciation (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Accumulated Depreciation data on file, last reported at $99.7 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $99.7 million, up 28.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.7 million (up 28.46% YoY), and the FY2025 annual result was $94.1 million, up 30.54% from the prior year.
• Accumulated Depreciation rose to $99.7 million in Q1 2026 per BEAM's latest filing, from $94.1 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $99.7 million in Q1 2026 and troughed at $19.3 million in Q1 2022.
• A 5-year average of $56.9 million and a median of $55.6 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation surged 93.95% in 2022, then advanced 28.46% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $30.2 million in 2022, then jumped by 66.33% to $50.2 million in 2023, then jumped by 43.69% to $72.1 million in 2024, then jumped by 30.54% to $94.1 million in 2025, then rose by 5.95% to $99.7 million in 2026.
• Business Quant data shows BEAM's Accumulated Depreciation at $99.7 million in Q1 2026, $94.1 million in Q4 2025, and $88.6 million in Q3 2025.